EU APPROVES MITAPIVAT | A New Treatment Milestone for Adults with α- or β-Thalassaemia

This decision is of particular importance because it covers a broad adult thalassaemia population, including both alpha- and beta-thalassaemia and both transfusion-dependent and non-transfusion-dependent disease. According to Agios Pharmaceuticals’ official press release, PYRUKYND is now the only medicine approved in all European Union Member States for adults across this broad thalassaemia indication.

Mitapivat is an oral pyruvate kinase activator. Its mechanism is based on activating the red blood cell form of pyruvate kinase, an enzyme involved in cellular energy production. By supporting red blood cell metabolism, mitapivat aims to address biological processes linked to anaemia in thalassaemia, a disease characterised by ineffective erythropoiesis, haemolysis, and reduced haemoglobin production.

The European Commission’s approval follows the positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use. It is based on the Phase 3 ENERGIZE and ENERGIZE-T studies. These were global, randomised, double-blind, placebo-controlled trials evaluating mitapivat in adults with alpha- or beta-thalassaemia. ENERGIZE studied non-transfusion-dependent patients, while ENERGIZE-T studied transfusion-dependent patients.

The clinical evidence submitted for regulatory review addressed outcomes that are highly meaningful in thalassaemia care. In non-transfusion-dependent thalassaemia, the evaluation included haemoglobin response and fatigue-related outcomes. In transfusion-dependent thalassaemia, the evaluation focused on transfusion-reduction response, an endpoint directly linked to transfusion burden and its associated clinical and quality-of-life implications.

The approval also has an important access dimension. Avanzanite Bioscience, Agios’ partner in Europe, has announced that it will commercialise and distribute PYRUKYND across Europe under its exclusive agreement with Agios and will work with local authorities to support access for adult patients with thalassaemia. This will be a crucial next step, as the impact of any new therapy depends not only on regulatory authorisation but also on actual patient access within national health systems.

With this EU decision, mitapivat has now been approved for thalassaemia in the United States, Saudi Arabia, the United Arab Emirates, and the European Union. The EU authorisation applies across EU Member States: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

TIF recognises this approval as an important development in a therapeutic area where unmet needs remain substantial. People with thalassaemia continue to face a lifelong disease burden that may include anaemia, fatigue, transfusion dependency, iron overload, organ complications, psychosocial impact, and unequal access to optimal care. New treatment options can contribute to better outcomes only when they are made available within strong, multidisciplinary, and patient-centred healthcare systems.

TIF therefore welcomes this regulatory milestone and emphasises the need for continued collaboration among regulators, healthcare professionals, national authorities, payers, patient organisations, and industry partners to ensure that eligible patients can benefit from scientific innovation in a timely, safe, and equitable manner.

Source: Agios Pharmaceuticals Press Release